Synthesis and biological evaluation of new series of benzamide derivatives containing urea moiety as sEH inhibitors

Bioorg Med Chem Lett. 2022 Aug 15:70:128805. doi: 10.1016/j.bmcl.2022.128805. Epub 2022 May 19.

Abstract

The pharmacological inhibition of soluble epoxide hydrolase (sEH) was shown to reduce inflammation and pain. Herein, we described a series of newly synthesized sEH inhibitors with the trident-shaped skeleton. Intensive structural modifications led to the identification of compound B15 as a potent sEH inhibitor with an IC50 value of 0.03 ± 0.01 nM. Furthermore, compound B15 showed satisfactory metabolic stability in human liver microsomes with a half-time of 197 min. In carrageenan-induced inflammatory pain rat model, compound B15 exhibited a better therapeutic effect compared to t-AUCB and Celecoxib, which demonstrated the proof of potential as anti-inflammatory agents for pain relief.

Keywords: Benzamide derivatives; In vivo anti-inflammation; SEH inhibitor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Benzamides / pharmacology
  • Benzamides / therapeutic use
  • Enzyme Inhibitors* / chemistry
  • Epoxide Hydrolases*
  • Pain
  • Rats
  • Structure-Activity Relationship
  • Urea / pharmacology
  • Urea / therapeutic use

Substances

  • Benzamides
  • Enzyme Inhibitors
  • Urea
  • Epoxide Hydrolases